N6-methyladenine-modified DNA was decreased in Alzheimer’s disease patients

doi:10.12998/wjcc.v10.i2.448

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4331)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

197

WORD

HTML

2150

Figures (1-3)

241

Tables (1-1)

245

Sum=2886

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

225

Download

533

Sum=758

Publishing Process of This Article

Item

Count

Browse

227

Download

460

Sum=687

Jan 14, 2022 (publication date) through Sep 8, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jan 14, 2022; 10(2): 448-457
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.448

Table 1 Characteristics of the study population

		Total (326)	AD (179)	NC (147)	P value
Age (yr)		73 (64, 78)	74 (68, 78)	72 (62, 79)	0.165
Sex (male/female)		168/158	91/88	77/70	0.781
m6A%		0.010% (0.008%, 0.014%)	0.010% (0.006%, 0.013%)	0.011% (0.009%, 0.014%)	0.002^a
MoCA score		24 (18, 26)	18 (14, 21)	26 (25, 28)	0.001^a
Education (yr)		12 (9, 15)	12 (9, 15)	11 (9, 15)	0.435
BMI (kg/cm²)		22.29 (20.16, 24.51)	22.27 (20.03, 24.58)	22.31 (20.32, 24.62)	0.460
Smoking (%)		69 (21.66)	31 (17.32)	38 (25.85)	0.061
Alcohol (%)		107 (32.82)	56 (31.28)	51 (34.69)	0.514
SBP (mmHg)		129 (115, 140)	127 (117, 138)	130 (113, 143)	0.434
DBP (mmHg)		77(69, 83)	75 (68, 83)	78 (69, 84)	0.265
APOE (%)	ε2/2	1 (0.31)	0 (0)	1 (0.68)
Allele (%)	ε2/3	26 (7.98)	12 (6.70)	14 (9.52)
	ε3/3	195 (59.82)	98 (43.58)	97 (65.99)
	ε3/4	89 (27.30)	57 (31.84)	32 (21.77)
	ε4/4	15 (4.60)	12 (6.70)	3 (2.04)

^aP < 0.01.

Baseline data are described by medians and interquartile ranges (IQRs). Two-group comparisons, such as the analysis of differences in baseline characteristics between Alzheimer’s disease and normal control, were analyzed by two independent-samples Mann-Whitney U tests (unpaired). AD: Alzheimer’s disease; NC: Normal control; SD: Standard deviation; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; APOE: Apolipoprotein E; MoCA: Montreal Cognitive Assessment.

Citation: Lv S, Zhou X, Li YM, Yang T, Zhang SJ, Wang Y, Jia SH, Peng DT. N6-methyladenine-modified DNA was decreased in Alzheimer’s disease patients. World J Clin Cases 2022; 10(2): 448-457
URL: https://www.wjgnet.com/2307-8960/full/v10/i2/448.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i2.448